October Publications - Parameters for Primary Care Physician HCV Treatment
Here are some updates to get you started.
News
Bloomberg
While prices for new, breakthrough treatments for cancer and hepatitis C have drawn scrutiny, companies like Valeant have come under fire for acquiring older ...
Patients with Hepatitis C Virus Often Do Not Know They Are Infected
Oct 14, 2015 | Rachel Lutz
More than three-quarters of intravenous drug users and Baby Boomers tested for hepatitis C were positive and unaware they were infected, according to results of a study published in the journal Annals of Emergency Medicine.
October 13, 2015
Medline Industries announced the initiation of a voluntary recall of uncoated compressed acetaminophen 500mg tablets at the consumer level due to incorrect labeling.
Drug use has hepatitis C on the rise among suburban youth
A resurgence of hepatitis C, a curable disease that is being found in heroin users, is following a national trend of increases in New Jersey, according to a new ...
Medline Industries announced the initiation of a voluntary recall of uncoated compressed acetaminophen 500mg tablets at the consumer level due to incorrect labeling.
Drug use has hepatitis C on the rise among suburban youth
A resurgence of hepatitis C, a curable disease that is being found in heroin users, is following a national trend of increases in New Jersey, according to a new ...
October 14, 2015
By: Sylvia Mathews Burwell, HHS Secretary
If you’ve read the HHS blog before, you might have seen Blair Hubbard’s story.
Blair fought back from an addiction to heroin and prescription opioids that nearly took her life. Today she volunteers as a peer recovery support team member at the clinic that saved her, and she works part time on an HIV/Hepatitis C survey for the CDC. And to help others who are struggling with addiction, she’s working on getting her masters so she can be a professional counselor.
Tue, 10/13/15 - 15:26
By David Douglas
In the early stages of chronic infection with hepatitis C virus (HCV), fibrosis stage on biopsy may help predict which patients should be treated promptly and which can wait, according to researchers at the Centers for Disease Control and Prevention (CDC).
By: Sylvia Mathews Burwell, HHS Secretary
If you’ve read the HHS blog before, you might have seen Blair Hubbard’s story.
Blair fought back from an addiction to heroin and prescription opioids that nearly took her life. Today she volunteers as a peer recovery support team member at the clinic that saved her, and she works part time on an HIV/Hepatitis C survey for the CDC. And to help others who are struggling with addiction, she’s working on getting her masters so she can be a professional counselor.
In Case You Missed It
A Ribavirin-Free Regimen for HCV Genotype 1b Infection
Atif Zaman, MD, MPH reviewing Lawitz E et al. Gastroenterology
Oct 14
Promising efficacy and safety results for a once-daily combination regimen, even in prior null responders and patients with cirrhosis
Current interferon-free regimens are highly effective in the treatment of hepatitis C virus (HCV) genotype 1 infection, but other HCV genotypes still require treatment with ribavirin, which can cause problematic cases of anemia, pruritus, and insomnia in certain patients.
In an ongoing industry-funded phase IIb study of a once-daily combination pill of ombitasvir, paritaprevir, and ritonavir (currently FDA-approved for use with dasabuvir, ribavirin, or both for HCV genotype 1a or 1b infection) with or without ribavirin in patients with HCV genotype 1b or 4 infection, researchers assessed sustained virologic response 12 weeks after the end of treatment (SVR12) in several subgroups. These included 82 patients without cirrhosis (42 treatment-naive and 40 treatment-experienced [with peginterferon and ribavirin]) treated for 12 weeks and 99 patients with cirrhosis (47 treatment-naive and 52 treatment-experienced) treated for 24 weeks.
In patients without cirrhosis, SVR12 rates were 95.2% and 90.0% in treatment-naive and treatment-experienced patients, respectively. Among patients with cirrhosis, SVR12 rates were 97.9% and 96.2% in treatment-naive and treatment-experienced patients, respectively. Only one patient discontinued treatment owing to a study drug–related adverse effect. Headache, asthenia, pruritus, and diarrhea were the most frequently reported adverse effects.
COMMENT
A 12-week or 24-week course of this single-pill combination regimen without ribavirin resulted in SVR rates ≥90% in patients with HCV genotype 1b, even those with cirrhosis or prior failure on peginterferon and ribavirin, and had an excellent safety profile. These findings bring us one step closer to the goal of an interferon-free, ribavirin-free, pangenotypic, single-pill regimen in all HCV-infected populations.
EDITOR DISCLOSURES AT TIME OF PUBLICATION
Disclosures for Atif Zaman, MD, MPH at time of publicationNothing to disclose
CITATION(S):
Lawitz E et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology 2015 Oct; 149:971. (http://dx.doi.org/10.1053/j.gastro.2015.07.001)
A Ribavirin-Free Regimen for HCV Genotype 1b Infection
Atif Zaman, MD, MPH reviewing Lawitz E et al. Gastroenterology
Oct 14
Promising efficacy and safety results for a once-daily combination regimen, even in prior null responders and patients with cirrhosis
Current interferon-free regimens are highly effective in the treatment of hepatitis C virus (HCV) genotype 1 infection, but other HCV genotypes still require treatment with ribavirin, which can cause problematic cases of anemia, pruritus, and insomnia in certain patients.
In an ongoing industry-funded phase IIb study of a once-daily combination pill of ombitasvir, paritaprevir, and ritonavir (currently FDA-approved for use with dasabuvir, ribavirin, or both for HCV genotype 1a or 1b infection) with or without ribavirin in patients with HCV genotype 1b or 4 infection, researchers assessed sustained virologic response 12 weeks after the end of treatment (SVR12) in several subgroups. These included 82 patients without cirrhosis (42 treatment-naive and 40 treatment-experienced [with peginterferon and ribavirin]) treated for 12 weeks and 99 patients with cirrhosis (47 treatment-naive and 52 treatment-experienced) treated for 24 weeks.
In patients without cirrhosis, SVR12 rates were 95.2% and 90.0% in treatment-naive and treatment-experienced patients, respectively. Among patients with cirrhosis, SVR12 rates were 97.9% and 96.2% in treatment-naive and treatment-experienced patients, respectively. Only one patient discontinued treatment owing to a study drug–related adverse effect. Headache, asthenia, pruritus, and diarrhea were the most frequently reported adverse effects.
COMMENT
A 12-week or 24-week course of this single-pill combination regimen without ribavirin resulted in SVR rates ≥90% in patients with HCV genotype 1b, even those with cirrhosis or prior failure on peginterferon and ribavirin, and had an excellent safety profile. These findings bring us one step closer to the goal of an interferon-free, ribavirin-free, pangenotypic, single-pill regimen in all HCV-infected populations.
EDITOR DISCLOSURES AT TIME OF PUBLICATION
Disclosures for Atif Zaman, MD, MPH at time of publicationNothing to disclose
CITATION(S):
Lawitz E et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology 2015 Oct; 149:971. (http://dx.doi.org/10.1053/j.gastro.2015.07.001)
By David Douglas
In the early stages of chronic infection with hepatitis C virus (HCV), fibrosis stage on biopsy may help predict which patients should be treated promptly and which can wait, according to researchers at the Centers for Disease Control and Prevention (CDC).
October Publications
HCV Next provides an overview of current hepatitis C topics, as well as content on all forms of viral hepatitis, and other liver related disease.
Table of Contents
5 QUESTIONS
A Conversation with Stevan A. Gonzalez, MD, MS
COVER STORY
Collaboration in Buffalo: How Liver Care is Changing the Face of a City
EDITORIAL
Parameters for Primary Care Physician HCV Treatment
IN THE JOURNALS
High Prevalence of HCV Found via Urban ED Screening
Interferon-Free Therapies Improve Liver Function in HCV Patients
Researchers find SVR from Incivek-Based Regimens Improved Liver Fibrosis Scores
Cytokines Influence Impaired Cognitive Function in Children with HCV
Gene Replicates HCV in Human Cells
SPECIAL SERIES
Continuum of Care: HCV and the Primary Care Provider
THE BIG PICTURE
Revising the Continuum of Care for Patients with Chronic Hepatitis C
Alexander Geboy, MS; Dawn Fishbein, MD MS
TREND WATCH
One in Four Patients with HCV Denied Initial Request for Treatment
European Commission Approves 12 Weeks of Daclatasvir/Sofosbuvir for HCV Genotype 3
5 QUESTIONS
A Conversation with Stevan A. Gonzalez, MD, MS
COVER STORY
Collaboration in Buffalo: How Liver Care is Changing the Face of a City
EDITORIAL
Parameters for Primary Care Physician HCV Treatment
IN THE JOURNALS
High Prevalence of HCV Found via Urban ED Screening
Interferon-Free Therapies Improve Liver Function in HCV Patients
Researchers find SVR from Incivek-Based Regimens Improved Liver Fibrosis Scores
Cytokines Influence Impaired Cognitive Function in Children with HCV
Gene Replicates HCV in Human Cells
SPECIAL SERIES
Continuum of Care: HCV and the Primary Care Provider
THE BIG PICTURE
Revising the Continuum of Care for Patients with Chronic Hepatitis C
Alexander Geboy, MS; Dawn Fishbein, MD MS
TREND WATCH
One in Four Patients with HCV Denied Initial Request for Treatment
European Commission Approves 12 Weeks of Daclatasvir/Sofosbuvir for HCV Genotype 3
Newsletter Update
The National Viral Hepatitis Roundtable
The National Viral Hepatitis Roundtable is a broad coalition working to fight, and ultimately end, the hepatitis B and hepatitis C epidemics. We seek an aggressive response from policymakers, public health officials, medical and health care providers, the media, and the general public through our advocacy, education, and technical assistance.
In This Issue
Join us! Twitter chat: "Liver Cancer is Preventable"
The Past, Present, and Future of Hepatitis C
Philadelphia Hepatitis C Grand Rounds
New Adult Vaccine Access Coalition Website
Clinical Toolkit from Rhode Island Defeats Hepatitis C
Viral Hepatitis Billing Codes Resource
RECENT ADDITIONS
Join us! Twitter chat: "Liver Cancer is Preventable"
The Past, Present, and Future of Hepatitis C
Philadelphia Hepatitis C Grand Rounds
New Adult Vaccine Access Coalition Website
Clinical Toolkit from Rhode Island Defeats Hepatitis C
Viral Hepatitis Billing Codes Resource
RECENT ADDITIONS
TUE, OCT 13, 2015 - 11:37
OASIS: A film about a community-based clinic treating current and former drug users for hepatitis C
OASIS takes viewers inside a struggling community-based clinic that specializes in treating current and former intravenous drug users for Hepatitis C. Follow this link to learn more and view a trailer.
Read More
Social Connections
FACEBOOK
TWITTER
The CDC National Prevention Information Network (NPIN)
OASIS: A film about a community-based clinic treating current and former drug users for hepatitis C
OASIS takes viewers inside a struggling community-based clinic that specializes in treating current and former intravenous drug users for Hepatitis C. Follow this link to learn more and view a trailer.
Read More
View a list of all NVHR newsletters, here.
Social Connections
The CDC National Prevention Information Network (NPIN)
The CDC National Prevention Information Network (NPIN) is the U.S. reference and referral service for information on HIV/AIDS, viral hepatitis, sexually transmitted diseases (STDs), and tuberculosis (TB). NPIN is a next-generation clearinghouse and collaborative community that collects and disseminates data and materials and enables prevention professionals on the international, national, state, and local levels to connect and share.
Connections Bimonthly e-Newsletter
The Connections Bimonthly e-Newsletter is a publication of the CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).
October Newsletters
HCV Advocate - October Mid-Month Newsletter
October Index
In case you missed this months collection of Hepatitis Newsletters, please click here to view October publications.
IDWeek 2015 took place in San Diego October 7-11, read ongoing conference highlights written by Liz Highleyman online at hivandhepatitis.com. Hot topics include; Overview and Hepatitis C Mortality Continues to Increase in the U.S.
Healio
Or jump over to Healio for clinical updates, data, and onsite video interviews with leading infectious disease experts who attended the meeting.
IDWeek 2015 In The News
Can Non-Invasive Tests Assess Fibrosis in Hepatitis?
Percutaneous liver biopsy is a proven way to rate the fibrosis stage both in hepatitis in chronic hepatitis C patients and hepatitis B patients. But it is uncomfortable for patients, risks complications and is prone to assembling errors.
Percutaneous liver biopsy is a proven way to rate the fibrosis stage both in hepatitis in chronic hepatitis C patients and hepatitis B patients. But it is uncomfortable for patients, risks complications and is prone to assembling errors.
October 14, 2015
Hepatitis C (HCV) is passed through contact with contaminated blood. We’ve noticed that many people new to the hepatitis C community want to know if HCV be transmitted through sex. So, we asked our...
Hepatitis C (HCV) is passed through contact with contaminated blood. We’ve noticed that many people new to the hepatitis C community want to know if HCV be transmitted through sex. So, we asked our...
By LB Herbert - October 12, 2015
While there are numerous symptoms associated with hepatitis C, fatigue is one of the most prominent and detrimental to a person’s overall quality of life. We asked our community to tell us...
While there are numerous symptoms associated with hepatitis C, fatigue is one of the most prominent and detrimental to a person’s overall quality of life. We asked our community to tell us...
By Daryl Luster - October 9, 2015
Advocacy is a word we hear often, and I use often when describing the work of supporting or speaking up for the hep c affected community. I call myself an advocate. There...
Advocacy is a word we hear often, and I use often when describing the work of supporting or speaking up for the hep c affected community. I call myself an advocate. There...
Tina
No comments:
Post a Comment